RFP
CATX icon

Root Financial Partners’s Perspective Therapeutics CATX Stock Holding History

Root Financial Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$8 – 3481
2025
Q4 		$8 Buy
+3
New +$9 ﹤0.01% 2422

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Root Financial Partners's CATX Position: Q1 2026 in Review

Root Financial Partners sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 3 shares — an estimated $8 sold.

Root Financial Partners first reported a position in CATX in Q4 2025 and held it in 1 quarter. The position peaked at $8 in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Root Financial Partners reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Root Financial Partners sold 3 Perspective Therapeutics shares in Q1 2026, an estimated $8.
  • Root Financial Partners first reported a position in Perspective Therapeutics in Q4 2025 and held it in 1 quarter.
  • Root Financial Partners's Perspective Therapeutics position peaked at $8 in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.